Nevertheless, the antigen combination of EpCAM and CD147, successfully detected in vivo derived CD147+EpCAM+ taMPs and their median values significantly increased in cancer patients by an average of 4.8 fold (Figure 1B and Table 1) across all investigated tumour entities. The gene discussed is EPCAM; the disease is cancer.